Table 2.
The contributions of platelets to the drug resistance of cancer cells.
| Model/Cell Types | Corresponding Drugs | Role of Platelets | Ref |
|---|---|---|---|
| Pancreatic ductal adenocarcinoma (PDAC) cells | Gemcitabine | Platelets modulate cytidine deaminase (CDD) and human equilibrative nucleoside transporter 1, the markers expression of gemcitabine resistance in pancreatic cells. Platelet-derived ADP and ATP can active survival signals of cancer cells through modulating Slug and CDD levels. | [130] |
| Non-small cell lung cancer | Gemcitabine/Cisplatin | Platelet activation index can be a potential marker for predicting gemcitabine/cisplatin resistance | [111] |
| Castration cancer patients | Abiraterone | Platelets harbor prostate cancer biomarkers and the ability to predict therapeutic response. | [112] |
| Immune thrombocytopenia patients | Rituximab | Lack of detectable platelet autoantibodies is associated with non-responsiveness to rituximab treatment. | [127] |
| Non-small cell lung cancer | Crizotinib | Platelets are useful for predicting and monitoring outcome of crizotinib. Platelets are valuable biomarkers for the non-invasive detection of EML4-ALK rearrangements. |
[131] |
| Serum in patients | Paclitaxel/Carboplatin | The platelet-sparing phenomenon could be observed in patients treated with carboplatin and paclitaxel chemotherapy. | [84] |